Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS).
Royalty Pharma Plc (RPRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AQR Capital Management Cliff Asness | 4,305,412 | $241,404,423 | +14% | 0.08% |
| 2. | Patient Capital Management Samantha Mclemore | 3,598,808 | $201,785,166 | -2% | 6.61% |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 2,500,000 | $140,175,000 | -67% | 0.2% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,450,669 | $137,409,011 | +16% | 0.11% |
| 5. | VGI Partners Robert M. P. Luciano | 2,447,879 | $137,252,575 | -7% | 7.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | $3,836,768.00 | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | $1,474,902.00 | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | $1,484,946.00 | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | $4,837,440.00 | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | $2,293,095.85 | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.97 | 100,000 | $5,997,250.00 | 370,401 | 2026-08-18 | Filing | |
| $59.14 | 1,772 | $104,798.74 | 0 | 2026-08-13 | Filing | |
| $58.59 | 9,230 | $540,752.47 | 1,772 | 2026-08-13 | Filing | |
| $55.88 | 9,099 | $508,453.94 | 0 | 2026-07-01 | Filing | |
| $57.09 | 600 | $34,254.00 | 40,000 | 2026-06-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 42,931,597 | $2,407,174,722 | 0.13% | |
| 2. | 35,273,770 | $1,977,800,284 | 0.41% | |
| 3. | 27,832,977 | $1,560,595,060 | 0.02% | |
| 4. | 24,513,814 | $1,374,489,542 | 0.06% | |
| 5. | 12,338,229 | $691,804,500 | 0.02% |
News See All
Astera Labs (ALAB) and Bloom Energy (BE) Soar as Investors Bet on S&P 500 Index (SPX) Inclusion
Astera Labs ($ALAB) and Bloom Energy ($BE) rose about 11% and 7%, respectively, on Friday. The move comes as traders bet both companies could be ad...
Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough
On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia...
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery.
3 ‘Perfect Ten’ Healthcare Stocks That Analysts Rate as a Strong Buy
We are diving into three healthcare stocks which all have a Strong Buy consensus and a 10 out of 10 TipRanks Smart Score. The Smart Score is a prop...
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Hedged Equity Fund”. A copy of the letter can be downloaded here.
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript May 6, 2026Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.53 EPS, expectations were $1.22.
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now.
8 Most Undervalued Biotech Stocks to Buy Right Now
In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now.
Hedge Fund Resource Center